Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Nat Commun. 2021 Jul 22;12(1):4457. doi: 10.1038/s41467-021-24813-2.
The role of cis-elements and their aberrations remains unclear in esophageal squamous cell carcinoma (ESCC, further abbreviated EC). Here we survey 28 H3K27ac-marked active enhancer profiles and 50 transcriptomes in primary EC, metastatic lymph node cancer (LNC), and adjacent normal (Nor) esophageal tissues. Thousands of gained or lost enhancers and hundreds of altered putative super-enhancers are identified in EC and LNC samples respectively relative to Nor, with a large number of common gained or lost enhancers. Moreover, these differential enhancers contribute to the transcriptomic aberrations in ECs and LNCs. We also reveal putative driver onco-transcription factors, depletion of which diminishes cell proliferation and migration. The administration of chemical inhibitors to suppress the predicted targets of gained super-enhances reveals HSP90AA1 and PDE4B as potential therapeutic targets for ESCC. Thus, our epigenomic profiling reveals a compendium of reprogrammed cis-regulatory elements during ESCC carcinogenesis and metastasis for uncovering promising targets for cancer treatment.
顺式作用元件及其异常在食管鳞状细胞癌(ESCC,进一步缩写为 EC)中的作用尚不清楚。在这里,我们调查了 28 个 H3K27ac 标记的活跃增强子谱和 50 个原发性 EC、转移性淋巴结癌(LNC)和相邻正常(Nor)食管组织的转录组。与 Nor 相比,在 EC 和 LNC 样本中分别鉴定出数千个获得或丢失的增强子和数百个改变的推定超级增强子,并且有大量共同获得或丢失的增强子。此外,这些差异增强子导致 EC 和 LNC 中的转录组异常。我们还揭示了推定的驱动致癌转录因子,其缺失会降低细胞增殖和迁移。用化学抑制剂抑制获得的超级增强子的预测靶标,发现 HSP90AA1 和 PDE4B 是 ESCC 的潜在治疗靶点。因此,我们的表观基因组图谱揭示了 ESCC 发生和转移过程中重新编程的顺式调控元件的概要,为癌症治疗发现有前途的靶点。